17,261 trials
HIV Infections
Primary: Percentage of Participants With HIV-ribonucleic Acid (RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Month 12…
Achondroplasia
Primary: Overall Summary of Adverse Events During Initial 6-Month Period — 8; 8; 10; 9 Participants
Lymphoma
Primary: Percentage of Participants With Overall Response — 25.0 percentage of participants
Lip and Oral Cavity Squamous Cell Carcinoma · Oral Cavity Verrucous Carcinoma · Precancerous Condition
Primary: Comparison Between Treatment Groups of the Within-patient Change in MVD Score Following Treatment Initiation
Chronic Myelogenous Leukemia
Primary: Percentage of Patients Who Are in MMR (Major Molecular Response) at 48 Weeks After Starting the Treatment-free Remission (TFR) Phase — 51.6 Percentage of participants
Pancreatic Adenocarcinoma · Resectable Pancreatic Carcinoma
Primary: R0 Resection Rate Defined as Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins by Pathologic Assessment — 42 percentage of participants…
Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Secondary Acute Myeloid Leukemia
Primary: Number of Participants With a Response — 3; 6; 7; 0 Participants
Gastro-Enteropancreatic Neuroendocrine Tumor
Primary: Relative Lesion Counts Presented by Combination of Injected Peptide/Radioactivity Dose Ranges — 3.6; 3.8; 2.1; 2.6 Ratio
Chronic Myeloid Leukemia
Primary: Percentage of Patients in Treatment Free Remission (TFR) Within 48 Weeks — 57.9 Percentage of participants
Castration-Resistant Prostate Carcinoma · Metastatic Malignant Neoplasm in the Bone · Metastatic Malignant Neoplasm in the Soft Tissues
Primary: Percentage of Participants With a >= 50% Decline in Prostate-specific Antigen (PSA) Value — 73.5 percentage of subjects
Narcolepsy · Excessive Sleepiness
Primary: Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) — 20.46; 19.08 centimeter (cm) — p=0.0022
Bladder Cancer
Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants
Glioblastoma
Primary: Progression Free Survival at 6 Month — 61.3; 55.7 percentage of patients
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndrome
Primary: Transplant-related Mortality (TRM) — 13 Kaplan-Meier estimates (%)
Breast Cancer
Primary: Number of Patients Who Developed Grade 2-3 Acute Radiation Dermatitis Within 60 Days Post-RT — 8 Participants